Biopharma & Life Sciences
Wave Life Sciences Executive Compensation (FY25)
WVE · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025 ◇ Paul Bolno | Latest say-on-pay support = August 5, 2025 |
Velarion Intel, $5,000/year: one seat · one year · every company we cover, with dashboards, peer screens and board-ready briefs.
The Wave Life Sciences brief, $500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $900.
Data as of November 5, 2026Latest filing (DEF 14A): October 14, 2026
9 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Velarion Intel, one year, every company
220 figures on this page: 213 cited to the filing that reported them, 7 calculated from figures it prints. See the citations
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Paul Bolno: $4,272,299 → $12,277,916 (187.4% higher)
Frequently asked questions
Answers drawn from the data on this page.
Who is Wave Life Sciences' chief executive and what were they paid?
Paul Bolno was paid $12,277,916 in total compensation as President and Chief Executive Officer for fiscal 2025. Bolno's total was 187.4% higher than the $4,272,299 reported for fiscal 2024.
What was Wave Life Sciences' say-on-pay result?
The say-on-pay proposal drew 99.3% of votes cast for or against in favor at the meeting held August 5, 2025 for fiscal 2024.
Which companies are in Wave Life Sciences' peer group?
The disclosed peer group names Alector, Inc., Arcturus Therapeutics Holdings, Inc., Arrowhead Pharmaceuticals, Inc., Avidity Biosciences, Inc. and Beam Therapeutics, Inc., among others.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Paul Bolno President and Chief Executive Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Chandra Vargeese Chief Technology Officer, Head of Platform Discovery Sciences | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Kyle Moran Chief Financial Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Christopher Francis Senior Vice President, Corporate Development and Head of Emerging Areas | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Paul Bolno President and Chief Executive Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Chandra Vargeese Chief Technology Officer, Head of Platform Discovery Sciences | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Kyle Moran Chief Financial Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Christopher Francis Senior Vice President, Corporate Development and Head of Emerging Areas | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Paul Bolno President and Chief Executive Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Kyle Moran Chief Financial Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Chandra Vargeese Chief Technology Officer, Head of Platform Discovery Sciences | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Christopher Francis Senior Vice President, Corporate Development and Head of Emerging Areas | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Paul Bolno President and Chief Executive Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Kyle Moran Chief Financial Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Chandra Vargeese Chief Technology Officer, Head of Platform Discovery Sciences | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Christopher Francis Chief Strategy Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Chandra Vargeese | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Chandra Vargeese | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Christopher Francis | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Christopher Francis | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Kyle Moran | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Kyle Moran | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Paul B. Bolno | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Paul B. Bolno | RSU | ◇ | — | — | ◇ | — | — | ◇ |
Fiscal 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Paul Bolno | Option | ◇ | — | ◇ | 2/4/2035 |
| Option | ◇ | — | ◇ | 2/5/2034 | |
| Option | ◇ | — | ◇ | 2/17/2033 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 1/1/2032 | |
| RSU | ◇ | ◇ | — | — | |
| Kyle Moran | Option | ◇ | — | ◇ | 2/4/2035 |
| Option | ◇ | — | ◇ | 2/5/2034 | |
| Option | ◇ | — | ◇ | 2/17/2033 | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 1/1/2032 | |
| Chandra Vargeese | Option | ◇ | — | ◇ | 2/4/2035 |
| Option | ◇ | — | ◇ | 2/5/2034 | |
| Option | ◇ | — | ◇ | 2/17/2033 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 1/1/2032 | |
| Christopher Francis | Option | ◇ | — | ◇ | 2/5/2034 |
| Option | ◇ | — | ◇ | 2/4/2035 | |
| Option | ◇ | — | ◇ | 2/17/2033 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 1/1/2032 |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Aik Na Tan | ◇ | ◇ | ◇ | — | — | — | ◇ |
Christian Henry Board chair | ◇ | ◇ | ◇ | — | — | — | ◇ |
Mark H. N. Corrigan, M.D | ◇ | ◇ | ◇ | — | — | — | ◇ |
Adrian Rawcliffe | ◇ | ◇ | ◇ | — | — | — | ◇ |
Heidi L. Wagner, J.D | ◇ | ◇ | ◇ | — | — | — | ◇ |
Peter Kolchinsky | — | — | — | — | — | — | — |
Gregory L. Verdine | — | — | — | — | — | — | — |
Ken Takanashi | ◇ | ◇ | ◇ | — | — | — | ◇ |
Paul B. Bolno, M.D., MBA served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board chair premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Equity is delivered as Rsus/Options.
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- Alector, Inc. ALEC
- Arcturus Therapeutics Holdings, Inc. ARCT
- Arrowhead Pharmaceuticals, Inc. ARWR
- Avidity Biosciences, Inc. RNA
- Beam Therapeutics, Inc. BEAM
- Denali Therapeutics Inc. DNLI
- Dyne Therapeutics, Inc. DYN
- Editas Medicine, Inc. EDIT
- Intellia Therapeutics, Inc. NTLA
- Ionis Pharmaceuticals, Inc. IONS
- Prime Medicine, Inc. PRME
- PTC Therapeutics, Inc. PTCT
- Stoke Therapeutics, Inc. STOK
- Verve Therapeutics, Inc. VERV
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2024 | August 5, 2025 | = | ◇ | ◇ | ◇ |
| 2023 | August 6, 2024 | = | ◇ | ◇ | ◇ |
| 2022 | August 1, 2023 | = | ◇ | ◇ | ◇ |
| 2021 | August 9, 2022 | = | ◇ | ◇ | ◇ |
| 2020 | August 10, 2021 | = | ◇ | ◇ | ◇ |
| 2019 | August 12, 2020 | = | ◇ | ◇ | ◇ |
| 2018 | August 8, 2019 | = | ◇ | ◇ | ◇ |
What this page does not include
Everything above is a fact Wave Life Sciences disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Wave Life Sciences sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $500Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
220 figures on this page: 213 cited to the filing that reported them, 7 calculated from figures it prints.
213 cited to the filing
7 calculated from the filing
Documents cited
- 0001193125-26-421806Executive Officer and Director Compensation
- 0001193125-25-178083Proposal 6 - Shareholders approved on a non-binding, advisory basis only, the compensation of the Company’s named executive officers, in the manner and on the basis set forth described in the Proxy St
- 0001193125-25-144678
- 0001193125-24-199020Proposal 6 - Shareholders approved on a non-binding, advisory basis only, the compensation of the Company’s named executive officers, in the manner and on the basis set forth described in the Proxy St
- 0001193125-23-205066Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001193125-22-221350Item 5.07 Submission of Matters to a Vote of Security Holders.
- 0001193125-21-247771Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001193125-20-223731Item 5.07 Submission of Matters to a Vote of Security Holders.
- 0001193125-19-221246Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Wave Life Sciences executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/WVE (accessed 2026).
Short form: data: Velarion
The Wave Life Sciences brief, $500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $900.
9 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Wave Life Sciences and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Biopharma & Life Sciences rankings
Peers Wave Life Sciences discloses
The companies named in WVE's own disclosed peer group.
Alector, Inc.Arcturus Therapeutics Holdings, Inc.Arrowhead Pharmaceuticals, Inc.Avidity Biosciences, Inc.Beam Therapeutics, Inc.Denali Therapeutics Inc.Dyne Therapeutics, Inc.Editas Medicine, Inc.Intellia Therapeutics, Inc.Ionis Pharmaceuticals, Inc.Prime Medicine, Inc.PTC Therapeutics, Inc.Stoke Therapeutics, Inc.Verve Therapeutics, Inc.
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}